AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway

[1]  Bo Hu,et al.  Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine , 2021, Frontiers in Oncology.

[2]  Shahid A. Khan,et al.  Medical therapies for intra-hepatic cholangiocarcinoma. , 2021, Journal of hepatology.

[3]  G. Zuo,et al.  Integrated bioinformatic analysis and experiment confirmation of the antagonistic effect and molecular mechanism of ginsenoside Rh2 in metastatic osteosarcoma. , 2021, Journal of pharmaceutical and biomedical analysis.

[4]  D. Mirza,et al.  The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis , 2020, Annals of hepato-biliary-pancreatic surgery.

[5]  Wenbo Li,et al.  Overexpression of the zinc-α2-glycoprotein accelerates apoptosis and inhibits growth via the mTOR/PTEN signaling pathway in gastric carcinoma cells. , 2019, Life sciences.

[6]  K. Ahn,et al.  Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular–clinical analysis and potential targeted approach , 2019, Hepatology International.

[7]  T. Pawlik,et al.  Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent , 2018, The British journal of surgery.

[8]  M. Kudo.  Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma , 2018, Liver Cancer.

[9]  G. Gores,et al.  Cholangiocarcinoma — evolving concepts and therapeutic strategies , 2018, Nature Reviews Clinical Oncology.

[10]  V. Mittal.  Epithelial Mesenchymal Transition in Tumor Metastasis. , 2018, Annual review of pathology.

[11]  T. Pawlik,et al.  Performance of prognostic scores and staging systems in predicting long‐term survival outcomes after surgery for intrahepatic cholangiocarcinoma , 2017, Journal of surgical oncology.

[12]  Gangqiang Ding,et al.  LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  E. Zhang,et al.  H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma , 2016, Nucleic acids research.

[14]  Jing Yang,et al.  Epithelial–mesenchymal transition in tumor metastasis , 2016, Molecular oncology.

[15]  Ting Liu,et al.  AZGP1 suppresses epithelial-to-mesenchymal transition and hepatic carcinogenesis by blocking TGFβ1-ERK2 pathways. , 2016, Cancer letters.

[16]  Andrew X. Zhu,et al.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise , 2016, The oncologist.

[17]  G. Sauter,et al.  Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG‐fusion positive and PTEN deleted prostate cancers , 2016, International journal of cancer.

[18]  F. Sassi,et al.  Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation , 2016, BMC Cancer.

[19]  K. Boudjema,et al.  Gene expression profiling of the tumor microenvironment in human intrahepatic cholangiocarcinoma , 2016, Genomics data.

[20]  Andrew L. Kung,et al.  Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.

[21]  M. Saitoh.  Epithelial–mesenchymal transition is regulated at post-transcriptional levels by transforming growth factor-β signaling during tumor progression , 2015, Cancer science.

[22]  K. Chitrala,et al.  Computational Prediction and Analysis of Breast Cancer Targets for 6-Methyl-1, 3, 8-Trichlorodibenzofuran , 2014, PloS one.

[23]  Masao Iwata,et al.  Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.

[24]  T. Pawlik,et al.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.

[25]  Toshima Z. Parris,et al.  Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma , 2014, International journal of cancer.

[26]  K. Boudjema,et al.  Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma , 2013, Hepatology.

[27]  Chun-yu Huang,et al.  Decreased Expression of AZGP1 Is Associated with Poor Prognosis in Primary Gastric Cancer , 2013, PloS one.

[28]  J. Gu,et al.  Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. , 2013, Carcinogenesis.

[29]  Hyun Goo Woo,et al.  Transcriptomic profiling reveals hepatic stem‐like gene signatures and interplay of miR‐200c and epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma , 2012, Hepatology.

[30]  Xue Xu,et al.  A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment , 2012, PloS one.

[31]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[32]  J. Yun,et al.  Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis , 2012, Journal of Translational Medicine.

[33]  A. Żaczek,et al.  Epithelial-Mesenchymal Transition: A Hallmark in Metastasis Formation Linking Circulating Tumor Cells and Cancer Stem Cells , 2012, Pathobiology.

[34]  J. Kench,et al.  Low AZGP1 expression predicts for recurrence in margin‐positive, localized prostate cancer , 2011, The Prostate.

[35]  H. Friess,et al.  AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling , 2010, Oncogene.

[36]  J. Everhart,et al.  Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. , 2009, Gastroenterology.

[37]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[38]  J. Kench,et al.  Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[39]  M. Rubin,et al.  Characterization of ZAG protein expression in prostate cancer using a semi‐automated microscope system , 2006, The Prostate.

[40]  Jiri Zavadil,et al.  TGF-β and epithelial-to-mesenchymal transitions , 2005, Oncogene.

[41]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.